Benchmark analyst Christopher Kuhn initiates coverage on Forward Air (NASDAQ:FWRD) with a Hold rating.
Disc Medicine Announces Presentation Of Initial Data From Phase 2 BEACON Trial In Patients With Erythropoietic Protoporphyria At European Hematology Association 2023 Congress
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,
